{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mayne KJ"],"funding":["Clinical Trial Service Unit and Epidemiological Studies Unit","Medical Research Council"],"pagination":["720-730"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616479"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(4)"],"pubmed_abstract":["Background
Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.Methods
The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg daily or matching placebo over a median of 2 years of follow-up. Serum uric acid was measured at randomisation then at 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen-Gill extension (total events). A post hoc composite outcome included new initiation of uric acid-lowering"],"journal":["Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"],"pubmed_title":["Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial."],"pmcid":["PMC7616479"],"funding_grant_id":["MC_UU_00017/4","MC_UU_00017/3"],"pubmed_authors":["Green JB","George J","Hooi L","Pontremoli R","Cheung AK","Ng SYA","Judge P","Haynes R","Kadowaki T","Nangaku M","Judge PK","Goto S","Deo R","Wanner C","Liu W","Sammons E","Herrington WG","Whelton P","Baigent C","EMPA-KIDNEY Collaborative Group","Rossello X","Sardell RJ","Landray MJ","Emberson J","Hauske SJ","Levin A","Bilous R","Hantel S","Li J","Bennett D","Brueckmann M","Cherney D","Hopley M","von-Eynatten M","Mayne KJ","Zhu D","Tuttle KR","Maggioni AP","Preiss D","Wittes J","Sandercock P","Cherney DZI","Staplin N","Liu ZH","Herzog C"],"additional_accession":[]},"is_claimable":false,"name":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.","description":"Background
Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.Methods
The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg daily or matching placebo over a median of 2 years of follow-up. Serum uric acid was measured at randomisation then at 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen-Gill extension (total events). A post hoc composite outcome included new initiation of uric acid-lowering","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-03T05:18:10.106Z","creation":"2025-04-04T08:21:43.669Z"},"accession":"S-EPMC7616479","cross_references":{"pubmed":["39277784"],"doi":["10.1093/ndt/gfae203"]}}